Celldex Therapeutics (NASDAQ:CLDX – Get Free Report) announced its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.96) EPS for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.06, FiscalAI reports. The firm had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.72 million.
Celldex Therapeutics Price Performance
Celldex Therapeutics stock traded up $1.60 during mid-day trading on Friday, reaching $29.87. The company had a trading volume of 926,313 shares, compared to its average volume of 1,242,830. The stock’s 50-day simple moving average is $32.93 and its 200-day simple moving average is $32.68. Celldex Therapeutics has a 1 year low of $22.10 and a 1 year high of $45.14. The company has a market capitalization of $2.35 billion, a P/E ratio of -6.95 and a beta of 1.04.
Analyst Ratings Changes
CLDX has been the topic of several recent analyst reports. Leerink Partners boosted their target price on Celldex Therapeutics from $70.00 to $88.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 23rd. Wells Fargo & Company raised their price target on Celldex Therapeutics from $48.00 to $72.00 and gave the company an “overweight” rating in a report on Wednesday, July 29th. Canaccord Genuity Group decreased their price target on Celldex Therapeutics from $62.00 to $60.00 and set a “buy” rating on the stock in a research note on Wednesday, July 22nd. Wall Street Zen raised Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, July 12th. Finally, Cantor Fitzgerald increased their price objective on Celldex Therapeutics from $61.00 to $72.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 22nd. Eleven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $63.08.
Get Our Latest Stock Analysis on Celldex Therapeutics
About Celldex Therapeutics
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing targeted therapeutics for diseases with significant unmet medical needs. The company uses antibody-based technologies to develop treatments intended to modulate the immune system and address inflammatory, autoimmune and other serious conditions.
Celldex’s lead investigational product is barzolvolimab, an antibody designed to selectively block the KIT receptor and reduce mast-cell activity.
Featured Stories
- Five stocks we like better than Celldex Therapeutics
- Dutch Bros Gave Wall Street What It Wanted, So Why Did the Stock Crater?
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
